193 related articles for article (PubMed ID: 36305958)
1. The "Understanding Pyoderma Gangrenosum, Review and Assessment of Disease Effects (UPGRADE)" Project: a protocol for the development of the core outcome domain set for trials in pyoderma gangrenosum.
Rick J; Gould LJ; Marzano AV; Garg A; Chen D; Oakes DL; Dissemond J; Herfarth H; Friedman MA; Alavi A; Yamamoto T; Gerbens LAA; Thomas KS; Ortega-Loayza AG
Arch Dermatol Res; 2023 May; 315(4):983-988. PubMed ID: 36305958
[TBL] [Abstract][Full Text] [Related]
2. A core domain set for pyoderma gangrenosum trial outcomes: an international eDelphi and consensus study from the UPGRADE initiative.
Jacobson ME; Rick JW; Gerbens LAA; Baghoomian W; Gould LJ; Marzano AV; Chen DM; Oakes DL; Dissemond J; Yamamoto T; Shinkai K; Nolan B; Lobato D; Thomas KS; Ortega-Loayza AG;
Br J Dermatol; 2024 Feb; 190(3):392-401. PubMed ID: 37952167
[TBL] [Abstract][Full Text] [Related]
3. Minimum data set for treatment effectiveness in pyoderma gangrenosum (MIDSTEP): an international protocol of an e-Delphi study to develop a clinical physician-driven treatment effectiveness registry on behalf of the UPGRADE initiative.
Haddadin OM; Jacobson ME; Chen DM; Croitoru DO; Dissemond J; Gontijo JRV; Hampton PJ; Kelly RI; Marzano AV; Tada Y; Gerbens LAA; Ortega-Loayza AG
Arch Dermatol Res; 2023 Dec; 315(10):2913-2919. PubMed ID: 37755505
[TBL] [Abstract][Full Text] [Related]
4. Eligibility Criteria for Active Ulcerative Pyoderma Gangrenosum in Clinical Trials: A Delphi Consensus on Behalf of the UPGRADE (Understanding Pyoderma Gangrenosum: Review and Assessment of Disease Effects) Group.
Kamal K; Xia E; Li SJ; Alavi A; Cogen AL; Firooz A; Marzano AV; Kaffenberger BH; Sibbald C; Fernandez AP; Callen JP; Dissemond J; Gontijo JRV; Shams K; Gerbens LA; French LE; Gould LJ; Bissonnette R; Shaigany S; Tolkachjov S; Yamamoto T; Wei-Ting Huang W; Ortega-Loayza AG; Mostaghimi A
J Invest Dermatol; 2024 Jun; 144(6):1295-1300.e6. PubMed ID: 38110114
[TBL] [Abstract][Full Text] [Related]
5. A core outcome domain set for clinical research on capillary malformations (the COSCAM project): an e-Delphi process and consensus meeting.
Langbroek GB; Wolkerstorfer A; Horbach SER; Spuls PI; Kelly KM; Robertson SJ; van Raath MI; Al-Niaimi F; Kono T; Boixeda P; Laubach HJ; Badawi AM; Rubin AT; Haedersdal M; Manuskiatti W; van der Horst CMAM; Ubbink DT;
Br J Dermatol; 2022 Nov; 187(5):730-742. PubMed ID: 35762296
[TBL] [Abstract][Full Text] [Related]
6. Development of a Core Outcome Set for Clinical Trials in Non-infectious Uveitis of the Posterior Segment.
Tallouzi MO; Mathers JM; Moore DJ; Bucknall N; Calvert MJ; Murray PI; Denniston AK;
Ophthalmology; 2021 Aug; 128(8):1209-1221. PubMed ID: 33515595
[TBL] [Abstract][Full Text] [Related]
7. Identification and evaluation of outcome measurement instruments in pyoderma gangrenosum: a systematic review.
Lu JD; Hobbs MM; Huang WW; Ortega-Loayza AG; Alavi A
Br J Dermatol; 2020 Nov; 183(5):821-828. PubMed ID: 32159849
[TBL] [Abstract][Full Text] [Related]
8. Vitiligo International Task force for an Agreed List of core data (VITAL): study protocol of a vitiligo core outcome set (COS) and contextual factors for clinical trials, registries, and clinical practice.
van Geel N; Hamzavi IH; Pandya AG; Wolkerstorfer A; Seneschal J; Garg A; Spuls P; Terwee CB; Mallett S; Speeckaert R; Meurant JM; Eleftheriadou V; Ezzedine K
Trials; 2022 Jul; 23(1):591. PubMed ID: 35871019
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
11. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
12. Identifying a Core Domain Set to Assess Psoriasis in Clinical Trials.
Callis Duffin K; Merola JF; Christensen R; Latella J; Garg A; Gottlieb AB; Armstrong AW
JAMA Dermatol; 2018 Oct; 154(10):1137-1144. PubMed ID: 29874367
[TBL] [Abstract][Full Text] [Related]
13. A core outcome set for clinical trials on non-specific low back pain: study protocol for the development of a core domain set.
Chiarotto A; Terwee CB; Deyo RA; Boers M; Lin CW; Buchbinder R; Corbin TP; Costa LO; Foster NE; Grotle M; Koes BW; Kovacs FM; Maher CG; Pearson AM; Peul WC; Schoene ML; Turk DC; van Tulder MW; Ostelo RW
Trials; 2014 Dec; 15():511. PubMed ID: 25540987
[TBL] [Abstract][Full Text] [Related]
14. Development of a core outcome domain set for clinical research on capillary malformations (the COSCAM project).
Langbroek GB; Wolkerstorfer A; Horbach SER; Spuls PI; Kelly KM; Robertson SJ; van Raath MI; Al-Niaimi F; Kono T; Boixeda P; Laubach HJ; Badawi AM; Troilius Rubin A; Haedersdal M; Manuskiatti W; van der Horst CMAM; Ubbink DT;
J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):1888-1895. PubMed ID: 34014582
[TBL] [Abstract][Full Text] [Related]
15. Development of a core outcome set for clinical trials in squamous cell carcinoma: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey.
Schlessinger DI; Iyengar S; Yanes AF; Chiren SG; Godinez-Puig V; Chen BR; Kurta AO; Schmitt J; Deckert S; Furlan KC; Poon E; Cartee TV; Maher IA; Alam M; Sobanko JF
Trials; 2017 Jul; 18(1):321. PubMed ID: 28701207
[TBL] [Abstract][Full Text] [Related]
16. Core outcome domains for clinical trials in non-specific low back pain.
Chiarotto A; Deyo RA; Terwee CB; Boers M; Buchbinder R; Corbin TP; Costa LO; Foster NE; Grotle M; Koes BW; Kovacs FM; Lin CW; Maher CG; Pearson AM; Peul WC; Schoene ML; Turk DC; van Tulder MW; Ostelo RW
Eur Spine J; 2015 Jun; 24(6):1127-42. PubMed ID: 25841358
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum: A Delphi Consensus of International Experts.
Maverakis E; Ma C; Shinkai K; Fiorentino D; Callen JP; Wollina U; Marzano AV; Wallach D; Kim K; Schadt C; Ormerod A; Fung MA; Steel A; Patel F; Qin R; Craig F; Williams HC; Powell F; Merleev A; Cheng MY
JAMA Dermatol; 2018 Apr; 154(4):461-466. PubMed ID: 29450466
[TBL] [Abstract][Full Text] [Related]
18. Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey.
Ma C; Panaccione R; Fedorak RN; Parker CE; Khanna R; Levesque BG; Sandborn WJ; Feagan BG; Jairath V
BMJ Open; 2017 Jun; 7(6):e016146. PubMed ID: 28601837
[TBL] [Abstract][Full Text] [Related]
19. Outcomes for Pressure Ulcer Trials (OUTPUTs): protocol for the development of a core domain set for trials evaluating the clinical efficacy or effectiveness of pressure ulcer prevention interventions.
Lechner A; Kottner J; Coleman S; Muir D; Bagley H; Beeckman D; Chaboyer W; Cuddigan J; Moore Z; Rutherford C; Schmitt J; Nixon J; Balzer K
Trials; 2019 Jul; 20(1):449. PubMed ID: 31331366
[TBL] [Abstract][Full Text] [Related]
20. Development of a core outcome set for clinical trials in rosacea: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey.
Iyengar S; Williamson PR; Schmitt J; Johannsen L; Maher IA; Sobanko JF; Cartee TV; Schlessinger D; Poon E; Alam M
Trials; 2016 Sep; 17(1):429. PubMed ID: 27580586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
